Nestlé divests its peanut allergy treatment business
Nestlé has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company that specialises in the diagnosis and treatment of allergies. The transaction was closed upon signing.
Last year, Nestlé announced it would conduct a strategic review of Palforzia. It will now receive milestone payments and ongoing royalties from Stallergenes Greer.
Greg Behar, CEO of Nestlé Health Science, said Nestlé is confident that Stallergenes Greer will take Palforzia forward, allowing Nestlé Health Science to focus on its strengths and growth drivers.
There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
What's on trend in the non-alcoholic beverage market?
Water and no/low-sugar carbonated drinks are now dominating the beverage aisle, according to a...
ARBS 2026 opens in one week
The refrigeration, air conditioning and building services sector event is running from 5–7...
Fonterra makes interim leadership changes for ingredients business
Prior to the start of Fonterra's new CEO on 1 May 2026, interim leadership changes have been...
